Stop by our booth #904 to learn how Quanterix's ultrasensitive biomarker technology is a critical component in researching Alzheimer's Disease.
Chat with our technology experts, read through our printed collateral on key biomarkers in neurology, and hear from some of the industry-thought leaders on the recent advancements in biomarker research.
For attendees of AAIC, the long-touted refrain of the promise of plasma biomarkers for Alzheimer’s disease diagnosis has resulted in tremendous advances in translational research. The time is nigh for those advances to move into the clinic, and Quanterix has been at the front lines of this effort. Join us as we review some of the landmark clinical studies supporting the translation of neurological biomarkers, such as phosphorylated Tau, Nf-L, and GFAP; delve into clinical validity, clinical utility, and intended uses for patient care; and lay out our roadmap to making these tests a reality.
You’ll come away with an appreciation of the practical realities of test translation, an overview of putative workflows for deployment to patients, and an opportunity to join us on our journey by keeping up to date on our advances at Quanterix.
Looking to have a more significant research discussion with one of our technical sales experts? Stop by booth #904 to get started and review our full portfolio of materials.